Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Sanduzzi-Zamparelli M, Matilla A, Lledo JL, Muñoz-Martínez S, Varela M, Iñarrairaegui M, Perelló C, Mínguez B, Llarch N, Márquez L, Guerrero A, Iserte G, Castaño-García A, Carrión L, Fortuny M, Rimola J, García-Criado Á, Domenech G, Torres F, Rios-Guillermo J, Boix L, Samper E, Kateb À, Bruix J, Reig M

Open source

DOI: 10.1111/apt.70578
Published: 2026 Apr
Container: Alimentary pharmacology & therapeutics
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/apt.70578,
  title = {Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).},
  author = {Sanduzzi-Zamparelli M and Matilla A and Lledo JL and Muñoz-Martínez S and Varela M and Iñarrairaegui M and Perelló C and Mínguez B and Llarch N and Márquez L and Guerrero A and Iserte G and Castaño-García A and Carrión L and Fortuny M and Rimola J and García-Criado Á and Domenech G and Torres F and Rios-Guillermo J and Boix L and Samper E and Kateb À and Bruix J and Reig M},
  year = {2026},
  journal = {Alimentary pharmacology \& therapeutics},
  doi = {10.1111/apt.70578},
  url = {https://doi.org/10.1111/apt.70578}
}

RIS

TY  - JOUR
TI  - Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).
AU  - Sanduzzi-Zamparelli M
AU  - Matilla A
AU  - Lledo JL
AU  - Muñoz-Martínez S
AU  - Varela M
AU  - Iñarrairaegui M
AU  - Perelló C
AU  - Mínguez B
AU  - Llarch N
AU  - Márquez L
AU  - Guerrero A
AU  - Iserte G
AU  - Castaño-García A
AU  - Carrión L
AU  - Fortuny M
AU  - Rimola J
AU  - García-Criado Á
AU  - Domenech G
AU  - Torres F
AU  - Rios-Guillermo J
AU  - Boix L
AU  - Samper E
AU  - Kateb À
AU  - Bruix J
AU  - Reig M
PY  - 2026
JO  - Alimentary pharmacology & therapeutics
DO  - 10.1111/apt.70578
UR  - https://doi.org/10.1111/apt.70578
ER  -

APA

M, S., A, M., JL, L., S, M., M, V., M, I., C, P., B, M., N, L., L, M., A, G., G, I., A, C., L, C., M, F., J, R., Á, G., G, D., F, T., J, R., L, B., E, S., À, K., J, B., & M, R. (2026). Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).. Alimentary pharmacology & therapeutics. https://doi.org/10.1111/apt.70578

Source records

pubmed · retrieved 2026-09-27T08:09:28.760Z